- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a Multicenter, Randomized, Double Blind, Parallel-group, Proof of Concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Subjects with Active Rheumatoid Arthritis despite Prior Treatment with Advanced Therapies (bDMARD or tsDMARD)
This study is looking at a new combination of two medicines, nipocalimab and certolizumab (Cimzia), for adults with rheumatoid arthritis that hasn't improved with other strong treatments. We want to see if this combination helps reduce symptoms and is safe after 12 weeks.
For: Rheumatoid ArthritisGermany · Poland · Hungary - AuthorisedTherapeutic use (Phase IV)
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.
This study looks at different ways to treat early rheumatoid arthritis, comparing standard treatments with newer biologic medicines. It also explores if medicine doses can be lowered for people who are getting better, aiming to find the most effective and safe long-term approaches.
For: Rheumatoid ArthritisIceland · Denmark · Norway